

# 53<sup>rd</sup> CONGRESS ERA-EDTA VIENNA AUSTRIA



Leading European Nephrology

MAY 21<sup>st</sup>-24<sup>th</sup>, 2016



Held jointly with  
Österreichische Gesellschaft  
für Nephrologie

## Industry Symposium Booklet



WWW.  
ERA-EDTA2016.ORG



Leading European Nephrology



[www.enp-era-edta.org](http://www.enp-era-edta.org)

## Industry Sponsored Symposia

53<sup>rd</sup> CONGRESS  
VIENNA AUSTRIA MAY 21<sup>st</sup>-24<sup>th</sup>, 2016  
ERA-EDTA

**Sunday, May 22, 2016**

**13:30-15:00**

Hall D ..... Fresenius Medical Care  
Hall E ..... Vifor Fresenius Medical Care Renal Pharma  
Hall B ..... B. Braun  
Hall C ..... Baxter Healthcare  
Hall G ..... Alexion Pharma International  
Hall K ..... Chiesi Farmaceutici  
Lounge 3 ... Shire International  
Hall N ..... Immunodiagnostic Systems & Natto Pharma

**18:45-19:45**

Hall G ..... Merck Sharp & Dohme  
Hall K ..... Amgen  
Hall N ..... Bayer

**Monday, May 23, 2016**

**13:30-15:00**

Hall D ..... Baxter Healthcare  
Hall E ..... Boehringer Ingelheim & Eli Lilly and Company  
Diabetes Alliance  
Hall F ..... Otsuka Pharmaceutical Europe  
Hall B ..... Vifor Fresenius Medical Care Renal Pharma  
Hall C ..... Astra Zeneca  
Hall G ..... Sanofi Genzyme  
Hall K ..... Novartis Pharma  
Hall M ..... NxStage Medical  
Hall N ..... Raptor Pharmaceuticals

**Tuesday, May 24, 2016**

**12:15-13:15**

Hall K ..... Sigma-Tau



Improving Outcomes of  
Advanced Chronic Kidney Disease Patients by

# Personalized and Precise Renal Replacement Therapy

**Chairmen:**  
**Professors Mariano Rodríguez Portillo (Spain)**  
**and Andrew Davenport (United Kingdom)**

## Fresenius Medical Care Scientific Symposium

### Cardiovascular Protection:

**How to balance benefit/risk by fluid  
and electrolytes management.**

Assoc. Professor Daniel Schneditz (Austria)

### Improving Intradialytic Stability:

**How to reduce the risk of  
extracorporeal thrombotic events.**


Professor Martin Kuhlmann (Germany)

### Uremic Toxicity, Gut-Kidney Axis and Renal Replacement Therapy:

**How to improve outcome of  
advanced CKD patients by a  
multi-targeted approach.**

Professor Griet Glorieux (Belgium)





53rd ERA-EDTA Congress 2016

# Protecting heart, vessels and bone – new ways to control phosphorus and potassium

**Sunday 22 May 2016**

**13:30–15:00**

**Hall E, Level 0**

**Austria Center Vienna**

## PROGRAMME

**13:30** Lunch boxes will be provided

**13:45–13:50** Chairs' introduction

Markus Ketteler (*Coburg, Germany*)

Alexander Rosenkranz (*Graz, Austria*)

**13:50–14:10** Hyperphosphataemia – understanding the challenges

Laurent Juillard (*Lyon, France*)

**14:10–14:30** Advances in the management of hyperphosphataemia

Philip Kalra (*Manchester, UK*)

**14:30–14:50** A new approach in potassium management – can we change the treatment paradigm?

Matthew R. Weir (*Maryland, USA*)

**14:50–15:00** Closing remarks and Q&A


Markus Ketteler, Alexander Rosenkranz

Dear Colleague,

It gives us great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled **Protecting heart, vessels and bone – new ways to control phosphorus and potassium**.

This educational programme offers insight from an international panel of experts, initially discussing the challenges faced in achieving phosphate control in haemodialysis patients and aspects that should be considered for optimizing management. Our second presentation looks at recent advances in hyperphosphataemia treatment, primarily focusing on iron-based, calcium-free phosphate binders that may offer a lower pill burden than previous treatments, thereby overcoming the challenge of patient non-adherence. Finally, we provide an overview of emerging therapies for hyperkalaemia that are suitable to use concomitantly with RAAS inhibitors in patients with chronic kidney disease.


This promises to be an engaging and informative programme and we encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.



Professor Markus Ketteler  
Chair



Professor Alexander Rosenkranz  
Co-Chair

Sponsored by  
 Vifor Fresenius Medical Care  
Renal Pharma

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organizer to hold the symposium and lunch boxes have been provided by the company.





## OPTIMAL TREATMENT TARGETS IN RENAL REPLACEMENT THERAPY - HOW TO ACHIEVE THEM?

SUNDAY 22 MAY 2016

Time: 13:30 - 15:00

Hall B

### PROGRAM & SPEAKERS

**"Tailor-made hemodialysate  
composition – effects on  
hemodynamic stability"**

Francesco Locatelli, Lecco, IT

**"Convection volume in HDF –  
lessons learned for daily practice"**

Peter J. Blankestijn, Utrecht, NL

**"Renal dose achievement in  
AKI – influential factors"**

Antoine Schneider, Lausanne, CH

### CHAIR

Joachim Hoyer, Marburg, GER



Visit our website:  
[www.bbbraun-dialysis.com](http://www.bbbraun-dialysis.com)

# Uremic toxins: urea, $\beta_2$ -microglobulin and beyond



### Scientific Chair and Faculty

Peter Stenvinkel, Stockholm, Sweden

### Faculty

Muriel Grooteman, Amsterdam, The Netherlands

Colin Hutchison, Hawke's Bay, New Zealand

### Industry Symposium

13:30–15:00, Sunday 22 May 2016

Hall C, Level 2 (red level)

Austria Center Vienna

*Lunch will be provided*

### Agenda

Sunday 22 May 2016

**Program start time:** 13:45

**Program duration:** one hour

### Program

Introductions and welcome

From low-flux HD to high-flux and HDF: what's next?

Uremic toxins beyond  $\beta_2$ m: what role do they play?

Albumin removal by dialysis: is there reason to be concerned?

Panel discussion and Q&A

Summary and close



Alexion Satellite Symposium at the 53rd Annual Scientific Meeting of the  
European Renal Association & European Dialysis and Transplant Association

# INVITATION

## TMA: multiple causes for a disease with 100 faces?

**Sunday 22 May 2016, 13:30-15:00**

Hall G - Level -2, Austria Centre Vienna

**Chair:** Dr Manuel Praga, Madrid, Spain

Please visit the Alexion booth in the  
industry exhibition area

Dear Colleagues,

It is our pleasure to invite you to attend the Alexion-sponsored satellite symposium at the  
53rd European Renal Association–European Dialysis and Transplant Association congress.

TMA: multiple causes for a disease with 100 faces?

The prognosis for patients with thrombotic microangiopathy (TMA) has evolved with the understanding of the critical role of complement activation. In this symposium we will discuss developments in the identification, differential diagnosis, and management of patients with TMA, with a particular focus on complement-related conditions. We will highlight the complexities of the differential diagnosis and how to navigate to a correct diagnosis, by guiding you through the evolution of clinical cases involving both the native and the transplanted kidney. We will also discuss the improved prognosis for patients with atypical haemolytic uraemic syndrome. Key to the successful management of TMA is being able to quickly and confidently make a differential diagnosis, and to rapidly initiate appropriate management strategies. Our interactive Q&A panel discussion aims to provide knowledge to aid the confident identification and management of patients with TMA.

On behalf of the faculty, I look forward to your participation in what will be an interesting and educational meeting.

Kind regards,

*Manuel Praga*

Chair

Professor of Medicine, Complutense University, Madrid, Spain.

### Programme

Welcome and introduction: Recognizing the many faces of TMA	Manuel Praga <i>Madrid, Spain</i>
Facing the future: rapid differential diagnosis of TMA	Christian Haas <i>Lübeck, Germany</i>
The changing face of TMA diagnosis for the kidney transplant patient	Julien Zuber <i>Paris, France</i>
Q&A panel discussion	All faculty

Please visit the Alexion booth in the  
industry exhibition area

**Sunday, 22<sup>nd</sup> MAY, 2016**  
h 13:30/15:00 - Hall K, Level -2

## CHIESI PRODUCT SYMPOSIUM

### Advancements in immunosuppression: are all tacrolimus formulations the same?

Chaired by Prof. R. Oberbauer (Austria)

#### Control and optimization: the answer in PK

Prof. P. Marquet (France)

#### Management and clinical outcomes: the answer of the clinician

Prof. J. Pascual (Spain)

Lunch box will be available for the attendees.

### About Chiesi

Chiesi Farmaceutici S.p.A. was founded in 1935 and for decades has been a responsible partner for the medical community in both respiratory and specialty care areas.

During these years of collaboration, the company has grown to be a global pharmaceutical company with products in **respiratory** (Foster®, Atimos®) and **cardiovascular** (Iperiten®) areas, along with products in **neonatology** (Curosurf® and Peyona®) and in **cystic fibrosis** (Bramitob®).

Chiesi Group is now present with **26 affiliates worldwide**, **6 research centres** (Italy, UK, US, France, Sweden, Denmark) and **more than 4,000 employees**.

Thanks to its **pipeline** including some of the most promising molecules for the treatment of respiratory diseases and several rare diseases, Chiesi Group is confident of being able to continue its **growth in the future**, focusing equally on historical areas along with a **strong interest on advanced therapies and new special care areas**, such as **transplantation**. The signature of the agreement with Veloxis Pharmaceuticals for the commercialisation of a novel formulation of tacrolimus was the first important sign of Chiesi commitment in this new area.



# RARE DISEASES AND THE KIDNEY

## UNEXPLAINED STORY AND COMPLEXITY OF FABRY DISEASE

Co-Chairs:

Prof. Gere Sunder-Plassmann (Austria)

Prof. Olivier Devuyst (Switzerland)

## SYMPOSIUM

22 May 2016, 13:30 – 15:00

Lounge 3, Floor Level 1

At the 53rd ERA-EDTA Congress  
Vienna, Austria

Lunch will be provided

## AGENDA AND FACULTY

### Welcome and Introduction

→ Prof. Gere Sunder-Plassmann (Austria)

### Overview and Common Misdiagnosis of Rare Diseases in Nephrology

→ Prof. Olivier Devuyst (Switzerland)

### Pathophysiology and Treatment of Fabry Disease: It's Not as Simple as we May Think

→ Prof. Sandro Feriozzi (Italy)

### How to Identify Fabry Disease Among Renal Patients: The Importance of Screening

→ Dr. Pablo Neumann (Argentina)

### Q&A

This scientific programme will include information about a Shire-promoted product.  
INTSP/C-APROM/REP/15/0140h



## IDS and NattoPharma invite you to attend our lunchtime symposium

**Date & time:** Sunday 22nd May 2016, 13:30 – 15:00

Lunch boxes will be served from 13:30

**Location:** Hall N, Austria Center Vienna, Vienna, Austria

### The Infernal Triad: Matrix Gla-Protein, Vitamin K and Vascular Calcification

Vascular mineralisation is currently recognised as an actively regulated process where it was previously regarded as a passive end-stage process. The discovery that the vitamin K-dependent matrix Gla-protein (MGP) is a strong inhibitor of vascular calcification (VC) has opened novel avenues for risk assessment and monitoring disease progression. The distinguished international faculty presentations, led by Prof. Jürgen Floege and Prof. Etienne Cavalier, will focus on the burden of VC in chronic kidney disease (CKD) by Prof. Ziad Massy; review pivotal data supporting the linkage of VC and MGP by Dr. Leon Schurgers; essential roles of vitamin K2 and the need for a reliable measurement to quantify vitamin K status by Dr. Katarzyna Maresz.

## Programme

- **Chair's welcome and introduction**  
Prof. Dr. Jürgen Floege MD, FERA  
Director of the Department of Nephrology and Clinical Immunology  
Vice Dean of Medical School  
University of Aachen  
Germany
- **Vascular calcification in CKD patients**  
Prof. Ziad A. Massy, MD, PhD, FERA  
Chief, Division of Nephrology, Ambroise Paré Hospital  
Co-Director, INSERM U-1018  
Co-Director, CESP for UVSQ affairs  
CESP Team 5 (EpReC, Renal & Cardiovascular Epidemiology) UVSQ  
France
- **Vitamin K-dependent matrix Gla-Protein:  
a crucial switch to control ectopic mineralisation**  
Leon J. Schurgers, Ph.D.  
Associate Professor of Biochemistry  
Cardiovascular Research Institute Maastricht  
University Maastricht  
The Netherlands
- **Vitamin K2: an essential nutrient for cardiovascular health**  
Katarzyna Maresz, Ph.D.  
President of the International Science and Health Foundation  
Poland
- **Discussion**  
Prof. Dr. Jürgen Floege MD, FERA  
Prof. Etienne Cavalier, PhD. EuSpLM
- **Closing remarks**  
Prof Etienne Cavalier, PhD. EuSpLM  
Head, Department of Clinical Chemistry  
University of Liège, CHU Sart-Tilman  
Belgium



# Treatment of Hepatitis C in Patients With Chronic Kidney Disease: Challenges and Opportunities

Sunday, 22 May 2016  
18:45 – 19:45

Satellite Symposium  
Sponsored by MSD

### CHAIR

Marcus Säemann

Associate Professor  
Clinical Division of Nephrology  
and Dialysis  
Department of Medicine III  
Medical University of Vienna  
Vienna, Austria

### FACULTY

Annette Bruchfeld

Associate Professor  
Karolinska Institute  
Department of Renal Medicine,  
Karolinska University Hospital  
Huddinge  
Stockholm, Sweden

David Roth

Professor of Medicine  
University of Miami  
School of Medicine  
Miami, Florida

Austria Center Vienna  
**Hall G, Level-2**  
Vienna, Austria

**Chair:** Marcus Säemann (Austria)

### AGENDA

18:45 – 18:50	Welcome and Opening Remarks	Marcus Säemann
18:50 – 19:10	The Burden of Hepatitis C in Patients With Chronic Kidney Disease	Annette Bruchfeld
19:10 – 19:30	Therapeutic Options and Guidelines for the Treatment of Hepatitis C in Patients With Chronic Kidney Disease	David Roth
19:30 – 19:40	Q & A	Panel
19:40 – 19:45	Closing Remarks	Marcus Säemann

Where a 25-year legacy of innovation in chronic **HEPATITIS C** treatment<sup>1,2</sup> meets

## AN UNWAVERING COMMITMENT TO THE TASK AT HAND

### HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES<sup>3</sup>

According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: it claims the lives of approximately 500,000 people per year.<sup>4</sup> However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.

*Learn more about how MSD is addressing  
the task at hand by visiting **Hall G, Level-2***

**References:** 1. US Food and Drug Administration Drug Approval Package. [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set\\_Current\\_Drug&ApplNo=202258&DrugName=VICTRELIS&ActiveIngred=BOCEPREVIR&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.DrugDetails](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202258&DrugName=VICTRELIS&ActiveIngred=BOCEPREVIR&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.DrugDetails). Accessed January 22, 2016. 2. Drugs@FDA: FDA Approved Drug Products. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails>. Accessed January 22, 2016. 3. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. <http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/>. Accessed March 30, 2016. 4. World Health Organization. WHO Key Facts. Hepatitis C. <http://www.who.int/mediacentre/factsheets/fs164/en/>. Accessed March 30, 2016.

### Treating secondary hyperparathyroidism with calcimimetics; new insights

Sunday, 22 May | 18:45 - 19:45

53<sup>rd</sup> ERA-EDTA Congress, Vienna | Austria  
Austria Center Vienna, Hall K, Level-2

#### Chairman:

David Wheeler, **London | United Kingdom**

#### Programme:

18:30 Light buffet

18:45 Scientific programme starts

19:45 Scientific programme ends

#### Welcome and Introduction

David Wheeler

**London | United Kingdom**

#### Lessons learnt from the EVOLVE study

Jürgen Floege

**Aachen | Germany**

#### Etelcalcetide – A new injectable calcimimetic for the treatment of secondary hyperparathyroidism

Markus Ketteler

**Coburg | Germany**

**AMGEN**<sup>®</sup>

*Advancing the Science and  
Practice of Nephrology*

Amgen (Europe) GmbH  
Dammstrasse 23  
CH-6301 Zug  
Switzerland  
[www.amgen.com](http://www.amgen.com)

©2016 Amgen Inc. All rights reserved.  
EUHQ-NP-073-0216-124246





## Industry symposium

**Sunday 22 May, 18:45 –19:45**

**Hall N, Level 1**

Adverse cardiovascular events are the leading cause of death in patients with diabetic kidney disease (DKD). In this Bayer-sponsored symposium, a distinguished panel of experts will examine the link between renal and cardiovascular disease, and explore the benefits of current and emerging therapies in reducing cardiovascular risk in patients with DKD. Please join us for an informative and stimulating meeting.



**Science For A Better Life**

Bayer Pharma AG  
Müllerstrasse 168  
13353 Berlin  
Germany

### Welcome and introduction

Chair: Hermann Haller (Germany)

### Cardiovascular outcomes in patients with diabetic kidney disease: epidemiology and pathophysiology

Patrick Rossignol (France)

### Emerging therapies for reducing renal and cardiovascular risk in patients with diabetic kidney disease

Peter Rossing (Denmark)

### Summary and close

Hermann Haller

A light snack will be served from 18:45  
We look forward to seeing you at the symposium

# Optimizing the ESRD patient journey and RRT clinical-economic outcomes

## Industry Symposium

13:30–15:00, Monday 23 May 2016  
Hall D, Level -2 (brown level)  
Austria Center Vienna

*Lunch will be provided*

## Scientific Chair

Simon Davies, Stoke-on-Trent, UK

## Faculty

Wim van Biesen, Ghent, Belgium  
Eero Honkanen, Helsinki, Finland  
Claus Peter Schmitt, Heidelberg, Germany

## Agenda

Monday 23 May 2016  
**Program start time:** 13:45  
**Program duration:** one hour



## Program

Introductions and welcome

Challenging the deadly paradigm of RRT modality transitions: an integrated approach to the patient ESRD journey

Doing the right thing at the right time: shared decision-making with RRT modality selection

The role of RPM and telemedicine in optimizing RRT modality outcomes and facilitating healthy transitions

Panel discussion and Q&A

Summary and close



# ADPKD Treatment Update

An Otsuka-sponsored symposium



THINKING  
ADPKD

Bringing clarity to the evidence behind tolvaptan, identification of patients with rapidly progressing ADPKD and practical insights into the use of tolvaptan in the clinic

**Monday 23 May**  
**Lunchtime Symposium**  
**13:30–14:45**

**Hall F, Austria Center Vienna**  
**Chair: Professor Roser Torra**

Lunch bags will be provided at the start of the symposium.

## Programme

### Updated results of TEMPO 3:4

13:50 Professor Vicente Torres,  
Mayo Clinic College of Medicine,  
Minnesota, USA

### How to identify patients with rapidly progressing ADPKD

14:05 Professor Henrik Birn, Aarhus University,  
Aarhus, Denmark

### Initiation and maintenance of tolvaptan: From theory into practice and early insights from the clinic

14:15 Dr Roman-Ulrich Müller, University  
of Cologne, Cologne, Germany

### Panel discussion and Q&A session

14:30 Led by Professor Roser Torra,  
Autonomous University of Barcelona,  
Barcelona, Spain





53rd ERA-EDTA Congress 2016

# New insights into iron metabolism and deficiency

**Monday 23 May 2016**

**13:30–15:00**

**Hall B, Level 2**

**Austria Center Vienna**

## PROGRAMME

- 13:30**      **Lunch boxes will be provided**
- 13:45–13:50**   **Chair's introduction**  
Angel de Francisco (*Santander, Spain*)
- 13:50–14:10**   **ID prevalence in patients with CKD – a matter of definition?**  
Kai-Uwe Eckardt (*Erlangen, Germany*)
- 14:10–14:30**   **Iron pathophysiology – its complexity and our knowledge gaps**  
Tomas Ganz (*Los Angeles, USA*)
- 14:30–14:50**   **Diagnosing and treating ID/IDA – meeting your patient's needs**  
Jolanta Malyszko (*Bialystok, Poland*)
- 14:50–15:00**   **Closing remarks and Q&A**  
Angel de Francisco

Dear Colleague,

It gives us great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled **New insights into iron metabolism and deficiency**.

This educational programme offers expert perspective from an internationally renowned faculty, who will first provide an overview of iron deficiency prevalence and the associated burden of disease in patients with chronic kidney disease (CKD). We then turn to what is currently known about the pathophysiology of iron deficiency in order to unravel its complexity before finally considering how to optimize diagnosis and treatment of iron deficiency in your patients. We will look at the most appropriate iron treatment, with a focus on the clinical benefits and potential risks of intravenous iron therapy.


This promises to be an engaging and informative educational session. We encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.



Professor Angel de Francisco  
Chair



Professor Kai-Uwe Eckardt  
Co-Chair

Sponsored by  
 **Vifor Fresenius Medical Care**  
Renal Pharma

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organizer to hold the symposium and lunch boxes have been provided by the company.



# Management of Hyperkalemia: Challenges and Considerations in Patients with CKD

Invitation to a CME Symposium at the ERA-EDTA 2016 Congress, Vienna

**Monday, May 23, 2016**  
**13:30-15:00**  
**Hall C, Level +2**

## Purpose of Activity

Hyperkalemia is a serious disturbance with increasing prevalence and a new treatment paradigm. Oral ion exchangers should have value not only to reduce the acute threat of hyperkalemia but also to achieve and maintain normal serum potassium levels enabling optimal use of renin-angiotensin-aldosterone system (RAAS) inhibitors for which there are proven clinical benefits. This broadens the range of eligible patients, lengthens the time on treatment and extends the focus to include the outpatient arena. Although as a general rule all instances of hyperkalemia should be deemed actionable, the nature and urgency of appropriate actions depend heavily on clinical judgment and are influenced by the initial point of care. The purpose of this presentation is to bring forward some of the considerations that inform clinical judgments essential to the evaluation and management of hyperkalemia in the outpatient CKD arena. Program content includes a review of the cellular mechanisms that normally ensure potassium homeostasis, how these are affected by RAAS inhibitors, hyperkalemic risk assessment based on clinical trials, and characteristics of the ideal, current and emerging oral ion exchangers.

## Educational Objectives

After completing this activity, the participant should be better able to:

- 1: Review the mechanisms that regulate potassium balance, and how they are affected by RAAS inhibition.
- 2: Describe the pathophysiology of hyperkalemia as affected by underlying conditions that modify clinical outcomes.
- 3: Identify considerations that clarify the urgency of actionable degrees of hyperkalemia based on information from clinical trials.
- 4: Present information on emerging oral ion exchangers and how they may affect current practices.

## Target Audience

This activity has been designed to meet the educational needs of Nephrology professionals involved in the care of patients with kidney disease.

This symposium is funded by AstraZeneca



This activity is jointly provided by SynAptiv and The Med Ed Group, Inc.

## Agenda/Faculty

**13:30 Lunch**

**13:45 Introduction and Questions**

**Programme Chair**

**David Goldsmith, MA, MB, BChir**

Professor and Consultant Nephrologist  
Renal Unit, Guy's and St Thomas' Hospital  
London, UK

**13:55 Pathophysiology and Risk of Hyperkalemia**

**Johannes FE Mann, MD**

Professor of Medicine, Friedrich Alexander University of Erlangen, Germany  
International Scholar, Population Health Research Institute  
McMaster University, Canada

**14:15 Current and Emerging Options for Outpatient Treatment of Hyperkalemia**

**Martin H. de Borst, MD, PhD**

Tenure Track Assistant Professor and Consultant Nephrologist  
Department of Nephrology, University Medical Center Groningen  
Groningen, The Netherlands

**14:35 Summary / Questions / Assessment of Learning**

**Professor David Goldsmith**

**14:45 Panel Discussion / Question and Answer Session**


**All faculty led by Professor David Goldsmith**

**15:00 Closing Remarks / Meeting adjourned**

**Professor David Goldsmith**

## PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SynAptiv and The Med Ed Group, Inc. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians. SynAptiv designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



# SATELLITE SYMPOSIUM

## UNKNOWN UNKNOWN IN CHRONIC KIDNEY DISEASE

MONDAY 23<sup>rd</sup> MAY, 13:30 – 15:00

ROOM: HALL G (LEVEL -2)

CHAIR: PROF. ALBERTO ORTIZ

WHAT IS AN UNKNOWN UNKNOWN IN CHRONIC KIDNEY DISEASE?  
PREVALENCE OF UNDIAGNOSED PRIMARY AND SECONDARY CAUSES OF CKD  
PROF. GIUSEPPE CASTELLANO

UTILITY OF RENAL BIOPSIES IN DIAGNOSIS AND TREATMENT OF SECONDARY  
AND RARE CAUSES OF CKD  
PROF. ALBERTO ORTIZ


KDIGO CONFERENCE ON FABRY NEPHROPATHY:  
MANAGEMENT OF RARE CAUSES OF CKD  
DR. BOJAN VUJKOVAC

**LUNCH TO BE PROVIDED**

SANOFI GENZYME 







### Program Overview

This state-of-the-art satellite symposium will bring together a panel of international tuberous sclerosis complex (TSC) experts to discuss the identification and management of TSC-related renal manifestations, review current long-term data on the role of mTOR inhibition in patients with TSC, and provide renal specialists with an overview of management strategies to help preserve renal function. Through a series of brief evidence-based presentations, the audience will gain an increased knowledge and familiarity of renal complications associated with TSC and current treatment approaches. Throughout the 60-minute symposium, questions will be posed to the audience to allow for a broader understanding of preserving renal function in patients with TSC. The audience will also be able to submit questions to the panel to support further discussion and engagement. The chair will highlight recommendations for best practices in the management of TSC-related renal manifestations, and a short series of interactive questions will help gauge audience learning, assess remaining unmet needs, and reinforce key points.

### Program Objectives

- Raise awareness of the importance of identifying and treating TSC-related renal manifestations
- Provide the most current data on everolimus and the role of mTOR inhibition to renal specialists, highlighting longer-term data
- Deliver key TSC- and mTOR-related educational expertise to renal specialists to optimize the management of TSC-related renal manifestations

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.  
This program and/or material was developed for use outside of the US, intended for non-US healthcare professionals, and is to be used in accordance with local laws and regulations.

# Working to Preserve Renal Function in Patients With Tuberous Sclerosis Complex

**Monday, 23 May 2016**

13.30–14.00 Doors Open/Registration

14.00–15.00 Symposium

Hall K | Austria Center  
Vienna, Austria

### Program Agenda

14.00 – 14.05	Welcome and Introduction	J. Chris Kingswood, FRCP
14.05 – 14.20	Natural Course of Renal Function in Patients with TSC	Bernard Zonnenberg, MD
14.20 – 14.35	Current Monitoring Guidelines and Treatment Options for TSC-Related Renal Manifestations	Klemens Budde, MD
14.35 – 14.50	Safety and Efficacy of mTOR Inhibitors	J. Chris Kingswood, FRCP
14.50 – 15.00	Question and Answer Session	All Faculty

### Faculty

**J. Chris Kingswood, FRCP (Chair)**  
Royal Sussex County Hospital  
Brighton, UK

**Klemens Budde, MD**  
Charité Universitätsmedizin  
Berlin, Germany

**Bernard Zonnenberg, MD**  
University Medical Center Utrecht  
Utrecht, The Netherlands





## HALL M, LEVEL 1

### PROGRAM

Chairmen: Pr. Eric Goffin (Belgium) and Dr. Maxence Fichoux (France)

“

CHALLENGES  
TO IMPROVE  
HEMODIALYSIS  
OUTCOMES:  
**ARE FREQUENT AND  
HOME THE ANSWERS?**

”

Taking place during  
the 53<sup>rd</sup> ERA-EDTA Congress

**MONDAY • MAY 23, 2016 • 13:30 – 15:00**  
**VIENNA, AUSTRIA**

### “HOME HD: HOW IT LOOKS & HOW IT WORKS”

Dr. Shashidhar Cherukuri (United Kingdom)

### “THE SUITABLE PATIENT & PRESCRIBING HOME HD”

Dr. Natalie Borman (United Kingdom)

### “THE EUROPEAN EXPERIENCE: CLINICAL OUTCOMES FROM THE KHDNEY COHORT”

Dr. Per Westerlund (Sweden)

### “PATIENT EXPERIENCE: WHAT ARE THE SUCCESS FACTORS”

Dr. Hamed Fessi (France)







Leading European Nephrology



Held jointly with  
Österreichische Gesellschaft  
für Nephrologie

## Industry Symposium Booklet

### Rare Disease Expert Forum

Advancing the Management  
of Rare Diseases

Rare Renal Diseases  
Are Growing Up  
Lunch Symposium at the  
53<sup>rd</sup> ERA-EDTA Congress

Chaired by Prof. Rainer Oberbauer, Vienna

We are delighted to invite you to participate in the satellite symposium

#### **Rare Renal Diseases Are Growing Up,**

An eminent pan-European panel of experts will offer insights into the  
contemporary management and care of patients with rare renal tubulopathies.

We sincerely hope you can join us in what promises to be a very productive  
and impactful meeting.

**Monday, May 23<sup>rd</sup>, 2016 13:30 - 15:00**

Hall N - Level 1

**13:45** Chairman's welcome

Prof. Rainer Oberbauer, Vienna

**13:50** Cystinosis vs CKD: Growth and neurocognitive development in childhood

Dieter Haffner, Hannover

**14:05** Managing the Adolescent Patient

Larissa Kerecuk, Birmingham

**14:20** Cystinosis in Adults ; An Emerging Population

Albane Brodin-Sartorius, Paris

**14:30** Discussion

**14:40** Closing remarks

Lunch boxes will be provided



Visit us at the  
Raptor Pharmaceuticals  
Booth  
Booth No. 2.260

Visiting/Invoice Address: Graadt van Roggenweg 340, (Building D, 5<sup>th</sup> Floor) 3531 AH Utrecht, The Netherlands  
Business Address: Naritaweg 165, 1043 BW Amsterdam, The Netherlands

EU/PRO/0316/0020

53<sup>rd</sup> CONGRESS  
VIENNA AUSTRIA MAY 21<sup>st</sup>-24<sup>th</sup>, 2016  
ERA-EDTA

## Industry Symposium Booklet

### Rare Disease Expert Forum

Advancing the Management  
of Rare Diseases

Rare Renal Diseases  
Are Growing Up  
Lunch Symposium at the  
53<sup>rd</sup> ERA-EDTA Congress

Chaired by Prof. Rainer Oberbauer, Vienna

## THANK YOU for attending our Satellite Symposium

We are delighted to invite you to participate in the satellite symposium

#### **Rare Renal Diseases Are Growing Up,**

An eminent pan-European panel of experts will offer insights into the  
contemporary management and care of patients with rare renal tubulopathies.

We sincerely hope you can join us in what promises to be a very productive  
and impactful meeting.

**Monday, May 23<sup>rd</sup>, 2016 13:30 - 15:00**

Hall N - Level 1

**13:45** Chairman's welcome

Prof. Rainer Oberbauer, Vienna

**13:50** Cystinosis vs CKD: Growth and neurocognitive development in childhood

Dieter Haffner, Hannover

**14:05** Managing the Adolescent Patient

Larissa Kerecuk, Birmingham

**14:20** Cystinosis in Adults ; An Emerging Population

Albane Brodin-Sartorius, Paris

**14:30** Discussion

**14:40** Closing remarks

Lunch boxes will be provided



Visit us at the  
Raptor Pharmaceuticals  
Booth  
Booth No. 2.260

Visiting/Invoice Address: Graadt van Roggenweg 340, (Building D, 5<sup>th</sup> Floor) 3531 AH Utrecht, The Netherlands  
Business Address: Naritaweg 165, 1043 BW Amsterdam, The Netherlands

EU/PRO/0316/0020

### Sigma-Tau Symposium

Tuesday May 24, 12:15 - 1:15 pm  
Hall K - Level -2, Exhibition Floor

## Secondary Carnitine Deficiency in Dialysis Patients-Shall We Supplement it?

#### Chairpersons:

**Tim Ulinski**, Department of Pediatric Nephrology, Armand Trousseau Hospital, APHP, Paris, France

**Ronald J.A. Wanders**, Lab Genetic Metabolic Diseases, University of Amsterdam, The Netherlands

#### Speakers:

**Ronald J.A. Wanders**, Lab Genetic Metabolic Diseases, University of Amsterdam, The Netherlands *Carnitine in Human Health and Disease Including Genetic Metabolic Disorders*

**Stephanie Reuter Lange**, School of Pharmacy & Medical Sciences, University of South Australia *Characteristics of Dialysis-Related Carnitine Deficiency Effectiveness of L-carnitine for the Treatment of Erythropoietin-Resistant Renal Anaemia*

**Asha Moudgil**, Children's National Medical Center, Washington, DC, USA *Carnitine Levels, Myocardial Function and Survival Outcomes in Children Receiving Chronic Hemodialysis and Continuous Renal Replacement Therapy*

a lunch box will be distributed

Carnitine is a small compound, which plays a crucial role in human metabolism and is derived from exogenous dietary sources but also synthesized endogenously. In the first lecture, the current state of knowledge with respect to carnitine in human health and disease with particular emphasis on the various genetic metabolic diseases in which carnitine is involved, will be discussed.

The disturbance in carnitine homeostasis associated with haemodialysis treatment has been well described, with numerous studies demonstrating a significant and dramatic reduction in endogenous blood and tissue L-carnitine concentrations. This will be the topic of the second presentation.

For the first time, research work has conducted a randomised, double-blind, placebo-controlled to assess the efficacy of intravenous L-carnitine supplementation as an adjunct for the treatment of renal anaemia in chronic haemodialysis patients hyporesponsive to ESA treatment. It will be discussed the effectiveness of L-carnitine supplementation normalizing the carnitine pool and increasing the erythrocyte carnitine palmitoyltransferase activity with consequential increased red blood cell survival.

The last, but not least, presentation will focus on the records review of patients with acute kidney injury receiving continuous renal replacement therapy (CRRT) at Children's National Health System between 2011 and 2014 for total carnitine (TC), free carnitine (FC) levels, and survival outcomes.

In light of the high rate of carnitine deficiency in children receiving CRRT, and high risk of morbidity and mortality in this population, the data of an ongoing randomized, prospective, controlled clinical trial to investigate the effects of carnitine supplementation on myocardial function in children receiving CRRT ([www.clinicaltrials.gov](http://www.clinicaltrials.gov), NCT01941823) will be disclosed.

#### References:

- Disorders of mitochondrial fatty acyl-CoA beta-oxidation.* Wanders RJ, Vreken P, et al.; 1999, J Inher Metab Dis. Jun; 22(4):442-87.
- A general introduction to the biochemistry of mitochondrial fatty acid  $\beta$ -oxidation.* Houten SM, Wanders RJ; 2010, J Inher Metab Dis. Oct; 33(5):469-77.
- What is the value of L-carnitine level determination for carnitine supplementation in hemodialysis patients?* Reuter SE, Evans AM. Hemodial Int. 2013 Jul;17(3):335-8.
- Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.* Reuter SE, Evans AM. Clin Pharmacokinet. 2012 Sep 1;51(9):553-72.
- Carnitine deficiency in children receiving continuous renal replacement therapy.* Sgambat K, Moudgil A. Hemodial Int. 2015 Aug 11.
- Carnitine supplementation improves cardiac strain rate in children on chronic hemodialysis.* Sgambat K, Frank L, Ellini A, Sable C, Moudgil A. Pediatr Nephrol. 2012 Aug;27(8): 1381-7.



# Next Congresses



Leading European Nephrology

BEST PRACTICE RECOMMENDATIONS • NDT • CKJ  
EPIDEMIOLOGY COURSES • FELLOWSHIPS • REGISTRY  
WORKING GROUPS • YOUNG NEPHROLOGISTS' PLATFORM  
HIGHLIGHTS IN NEPHROLOGY • CONGRESSES • CME COURSES  
RESEARCH PROGRAMME • ONLINE EDUCATION

What  
ERA-EDTA  
Can do  
for you



[www.era-edta2017.org](http://www.era-edta2017.org)

Madrid, Spain  
June 3<sup>rd</sup> - 6<sup>th</sup> 2017